Effect of Peritoneal Fixation on Lymphocele Formation

Prostate Cancer Clinical Trial

— PerFix  

Official title:

Prospective Randomized Trial Evaluating the Effect of Peritoneal Flap Fixation on Symptomatic and Radiologic Lymphocele Formation Following Robot Assisted Radical Prostatectomy With Extended Pelvic Lymph Node Dissection (PerFix)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04853095
• Other study ID #: FNOl 00098892
• Status: Completed
• Phase: N/A
• Start date: December 1, 2019
• Est. completion date: January 1, 2022

Study information

• Verified date: December 2022
• Source: University Hospital Olomouc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The PerFix Trial aims to compare the use of peritoneal fixation technique to standard of care (no fixation) during robot-assisted radical prostatectomy with extended pelvic lymph node dissection (RARP + eLND) for the prevention of symptomatic and radiologic lymphocele formation.

Description:

Extended pelvic lymph node dissection (ePLND) is the most accurate staging tool to determine lymph node involvement in prostate cancer. As urologist perform this procedure more often now, thanks to the shift to more advanced and aggressive stages, the role of ePLND is expanding. The main complication of PLND is development of a collection of lymphatic fluid called a lymphocele. Lymphoceles can be associated with abdominal pain, lower urinary tract symptoms, bladder outlet obstruction, penile or scrotal edema, infection/sepsis, lower extremity swelling and deep vein thrombosis. They necessitate intervention in up to 10% of patients treated with RARP + ePLND which includes drainage or surgery. Radiologic incidence can be as high as around 50% of operated patients with unknown clinical relevance. Many interventions aimed at reducing the rate of lymphocele formation with limited success so far. Several retrospective studies suggested using peritoneal flap fixation technique which could direct the lymphatic fluid to the peritoneal cavity out of the pelvis and its ensure its reabsorption there. We hypothesize that peritoneal fixation can potentially lower the incidence of symptomatic and radiologic lymphocele formation. By preventing this potentially very dangerous complication, it could be very beneficial for a large group of patients suffering from aggressive localized prostate cancer who are scheduled for RARP + ePLND.

Our goal is to is to test this hypothesis in a randomized trial comparing the fixation technique to standard of care, i.e. no fixation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 260
• Est. completion date: January 1, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• Able to give informed consent

• Histologically proven high risk prostate cancer or intermediate risk cancer (=5% risk of nodal involvement on Briganti 2012 nomogram) according to European Association od Urology (EAU) risk groups

• Suitable for minimally-invasive surgery

Exclusion Criteria:

• Previous pelvic surgery or irradiation.

• Any type of clotting disorder.

• Patients unwilling to undergo CT scan

• Kidney failure, Hemodialysis

• American Society of Anesthesiology Classification> 3

• Existing contraindications for performing a lymph node dissection

Related Conditions & MeSH terms

• Lymphocele
• Lymphocele After Surgical Procedure
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Procedure:
• Peritoneal fixation (PerFix)
PerFix involves suturing the free end of the peritoneal flap left after RARP + ePLND to the pelvic wall near the symphysis of the pubic bones leaving two lateral openings for directing the lymphatic fluid out of the pelvis to the abdominal cavity.
• Standard of care
ePLND without peritoneal flap fixation

Locations

Country	Name	City	State
Czechia	University hospital Olomouc	Olomouc

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Olomouc

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with Symptomatic lymphocele	The number of participants with symptomatic lymphocele will be determined. Clinical symptoms, time of onset, the size of the lymphocele, location, number of Lymphoceles and intervention needed will be measured	3 months
Secondary	Number of participants with Radiologic lymphocele on pelvic CT scan	The number of participants with radiologic lymphocele on Pelvic CT scan will be determined together with the size, location and number of detected lymphoceles.	3 months
Secondary	Rate of severe (Clavien grade =3) complications	Incidence of adverse events in the Prefix group compared to control group (no PerFix) will be measured. Surgical complications will be evaluated according to Clavien-Dindo classification	3 months
Secondary	Change in lymphocele size	The change in lymphocele size during follow-up CT scan will be examined	1 year
Secondary	Number of participants with Occurrence of Any Venous Thromboembolism	Radiologic investigation will be done in case of by swelling or pain of the lower extremity and the number of any venous thromboembolism will be determined	6 months
Secondary	Perioperative outcomes	Perioperative outcomes (time of the surgery, blood loss and hospital stay) will be measured	30 days
Secondary	The effect of lymphocele on urinary incontinence	The rate of continent patients will be defined using pads needed per day. Continent equals to 0-1 pad per day.	1 year
Secondary	The effect of lymphocele on potency	Potency equals to 19 and more points in the International index of erectile function (IIEF5) questionnaire (scale 0-25), the higher the score, the better.	1 year
Secondary	The effect of lymphocele on lower urinary tract symptoms (LUTS)	Change in the International prostate symptom score (IPSS) questionnaire from the baseline will be assessed (scale 0-35, higher score means worse outcome).	1 year